ePrints

Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scope

Lookup NU author(s): Dr Josh Bennett, Dr Ethan SenORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. This guideline will provide up-to-date and evidence-based recommendations for the safe use of biologic and targeted synthetic DMARDs in individuals with inflammatory arthritis (IA) across the life course. Important updates from the 2019 iteration of this guideline will include the incorporation of newer pharmacotherapies (such as Janus kinase inhibitors) and an extension of the target clinical population to cover children and young people with IA. The guideline will be updated and produced in accordance with the British Society for Rheumatology protocol for developing clinical guidelines, updated 2023.

Publication metadata

Author(s): Ling SF, Bennett JL, Reid VJ, Ahmed S, Ahmad MM, Bennett S, Bukhari M, Carver T, Chatten M, Cooray S, Craig L, Donaghy C, Galloway J, Gibson M, Heaton R, Henderson H, Holroyd N, Kavirayani A, Kent A, Malik M, Melville A, Nasrin T, Ramli AW, Rawlings A, Rose-Parfitt E, Sammut L, Sen ES, Vaghela D, Vint A, Waller R, Williams EL, Youngstein T, Zhang J, Zhao SS, Holroyd C

Publication type: Article

Publication status: Published

Journal: Rheumatology Advances in Practice

Year: 2025

Volume: 9

Issue: 4

Online publication date: 14/10/2025

Acceptance date: 01/09/2025

Date deposited: 03/11/2025

ISSN (electronic): 2514-1775

Publisher: Oxford University Press

URL: https://doi.org/10.1093/rap/rkaf104

DOI: 10.1093/rap/rkaf104

Data Access Statement: No new data were generated or analysed in support of this document

Altmetrics

Share